Try
Guardant Health Inc.
GHUnited States
56 filed reports · 508 financial concepts · 2 earnings calls · 8 media appearances
Filed reports
56 reports · Sep 2018 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 9 operating metrics, 124 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Current · 8-KSEC EDGAR | 24 | 128 | Dec 2019 to Jun 2026 |
| Quarterly · 10-QSEC EDGAR | 24 | 4,880 | Sep 2018 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 8 | 4,111 | Dec 2018 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 8-K | Jun 30, 2026 | Jul 30, 2026 | 6 | Open |
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Jul 30, 2026 | 416 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | May 7, 2026 | 7 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 7, 2026 | 263 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 19, 2026 | 8 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 19, 2026 | 928 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Oct 29, 2025 | 281 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Oct 29, 2025 | 9 | Open |
| FY2025 Q2 | 8-K | Jun 30, 2025 | Jul 30, 2025 | 8 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Jul 30, 2025 | 183 | Open |
| FY2025 Q1 | 8-K | Mar 31, 2025 | Apr 30, 2025 | 6 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | Apr 30, 2025 | 183 | Open |
Financial data
508 concepts · 9,119 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial495 concepts · 8,783 facts · Dec 2016 to Jul 2026
- Cash cash equivalents restricted cash and restricted cash equivalents47 · Dec 2016 to Jun 2026
- Allocated share based compensation expense46 · Dec 2016 to Jun 2026
- Costs and expenses46 · Dec 2016 to Jun 2026
- General and administrative expense (US GAAP)46 · Dec 2016 to Jun 2026
- Income tax expense benefit46 · Dec 2016 to Jun 2026
- Investment income interest46 · Dec 2016 to Jun 2026
- Net income loss available to common stockholders basic46 · Dec 2016 to Jun 2026
- Operating income loss46 · Dec 2016 to Jun 2026
- Other comprehensive income loss net of tax46 · Dec 2016 to Jun 2026
- Other comprehensive income unrealized holding gain loss on securities arising during period net of tax46 · Dec 2016 to Jun 2026
- Other nonoperating income expense46 · Dec 2016 to Jun 2026
- Research and development expense46 · Dec 2016 to Jun 2026
- Revenue46 · Dec 2016 to Jun 2026
- Selling and marketing expense (US GAAP)46 · Dec 2016 to Jun 2026
- Stockholders equity (US GAAP)46 · Dec 2016 to Jun 2026
- Depreciation45 · Sep 2017 to Jun 2026
- Depreciation depletion and amortization45 · Dec 2016 to Jun 2026
- Increase decrease in accounts receivable45 · Dec 2016 to Jun 2026
- Increase decrease in inventories45 · Dec 2016 to Jun 2026
- Increase decrease in other operating assets45 · Dec 2016 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets45 · Dec 2016 to Jun 2026
- Net cash provided by used in financing activities45 · Dec 2016 to Jun 2026
- Net cash provided by used in investing activities45 · Dec 2016 to Jun 2026
- Net cash provided by used in operating activities45 · Dec 2016 to Jun 2026
Guidance5 concepts · 124 facts · Feb 2020 to Jul 2026
- Revenue Guidance48 · Feb 2020 to Jul 2026
- Free Cash Flow Guidance30 · Feb 2023 to Jul 2026
- Gross Margin Guidance22 · Feb 2024 to Jul 2026
- Revenue Growth Guidance22 · May 2022 to Feb 2026
- Net Income Guidance2 · Feb 2020
Geography1 concepts · 88 facts · Sep 2017 to Jun 2026
- Revenue88 · Sep 2017 to Jun 2026
Segment5 concepts · 64 facts · Dec 2022 to Jun 2026
- Net income loss14 · Dec 2022 to Jun 2026
- Reportable Segment14 · Dec 2022 to Jun 2026
- Revenue14 · Dec 2022 to Jun 2026
- Segment reporting other item amount14 · Dec 2022 to Jun 2026
- Cost of goods and services sold (US GAAP)8 · Mar 2024 to Jun 2026
Product1 concepts · 52 facts · Dec 2023 to Jun 2026
- Revenue52 · Dec 2023 to Jun 2026
KPI1 concepts · 8 facts · Dec 2024 to Mar 2026
- Deliveries8 · Dec 2024 to Mar 2026
Segments
204 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement geographical2 members · 88 facts
- Non Us44 · Sep 2017 to Jun 2026
- US44 · Sep 2017 to Jun 2026
Statement business segments1 member · 64 facts
- Reportable64 · Dec 2022 to Jun 2026
Product or service4 members · 52 facts
- Biopharma Data13 · Dec 2023 to Jun 2026
- Licensing Other13 · Dec 2023 to Jun 2026
- Oncology13 · Dec 2023 to Jun 2026
- Screening13 · Dec 2023 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary123 claims from 10 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary170 claims from 8 reports · Sep 2024 to Jun 2026
- Risk-factor changes7 claims from 1 reports · Dec 2025
- Risk factors142 risks from 2 annual reports · 2024 to 2025
Earnings calls
2 calls · May 2026 to Jul 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Jul 30, 2026
- FY2026 Q1May 7, 2026
Executive media
8 appearancesPodcasts, interviews and conference appearances by the company's executives, with their claims.
- Conference talks4 · Mar 2024 to Dec 2025
- Other appearances3 · Mar 2024 to Aug 2025
- Podcasts1 · Mar 2026
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.